Antibodies, as important immune molecules in living organisms, have high specificity and affinity, and can accurately recognize and bind antigens. However, natural antibodies often have issues such as insufficient affinity, poor stability, or strong immunogenicity, which limit their application in disease treatment and diagnosis. Therefore, antibody engineering has emerged, which improves the performance of antibodies by modifying and optimizing antibody molecules to meet specific application requirements.

Antibody engineering, as an important component of modern biotechnology, provides powerful tools for the treatment and diagnosis of diseases by modifying and optimizing antibody molecules. This article first outlines the basic principles of antibody engineering, and then provides a detailed introduction to the key technologies in antibody engineering, including gene recombination technology, directed mutagenesis technology, and gene fusion technology. In addition, this article also explores the application of antibody engineering in disease treatment and diagnosis, and looks forward to the future development trends of antibody engineering.

1. The basic principles of antibody engineering

The basic principle of antibody engineering is based on a deep understanding of the structure and function of antibody molecules. Antibody molecules are composed of heavy and light chains, which are connected by disulfide bonds to form the Y-shaped structure of the antibody. The antigen binding site of the antibody is located at the end of the Y-shaped structure, consisting of variable regions of heavy and light chains. The core idea of antibody engineering is to modify the variable region of antibodies and change their binding characteristics with antigens. This can be achieved by changing the amino acid sequence, introducing new glycosylation sites, and altering the constant region of the antibody. At the same time, antibody engineering can also use genetic engineering technology to fuse the genes of antibodies with other functional genes, producing fusion antibodies with new functions.

2. Key Technologies of Antibody Engineering

1. Gene recombination technology: Gene recombination technology is one of the core technologies of antibody engineering, which mainly includes the following steps: first, isolate antibody genes from antibody producing cells or genomic libraries through PCR and other technologies; Secondly, insert these gene fragments into suitable vectors to construct recombinant plasmids; Finally, the recombinant plasmid is introduced into host cells, such as Escherichia coli, yeast, or mammalian cells, through antibody expression transformation or transfection techniques. The key to gene recombination technology lies in selecting appropriate vectors and host cells, as well as optimizing expression conditions to ensure effective expression and correct folding of antibodies. In addition, to improve the affinity and specificity of antibodies, targeted modifications can be made to antibody genes, such as altering the sequence of the antibody's constant or variable regions.

2. Site directed mutagenesis technology: Site directed mutagenesis technology is an important method for precise modification of antibody gene sequences in antibody engineering. This technology achieves the replacement or deletion of specific amino acids in antibody molecules by introducing specific nucleotide mutations. The main steps of directed mutagenesis technology include primer design, polymerase chain reaction amplification, mutant screening, and validation. The application scope of directed mutagenesis technology is very wide, which can be used to optimize the affinity, stability, or immunogenicity of antibodies. For example, by changing the key amino acids that bind antibodies to antigens, the binding affinity of antibodies can be improved; By introducing glycosylation sites or deleting regions with strong immunogenicity, the immunogenicity of antibodies can be reduced.

3. Gene fusion technology: Gene fusion technology is the process of connecting different gene fragments together to form fusion proteins with new functions or optimized performance. In antibody engineering, gene fusion technology is commonly used to generate fusion antibodies with dual or multiple functions. The design of fusion antibodies is flexible and diverse, which can fuse the antigen binding domain of antibodies with other functional proteins (such as enzymes, cytokines, etc.), achieving synergistic effects between antibodies and other biomolecules. In addition, gene fusion technology can also be used to produce antibodies with special properties, such as antibodies with longer half-lives or antibodies that can penetrate the blood-brain barrier.

4. Antibody Fragment Technology: Antibody fragment technology refers to the process of cutting complete antibody molecules into smaller fragments, such as Fab, F (ab ') 2, Fv, or single chain antibodies (scFv). These fragments retain the antigen binding ability of the antibody, but have smaller molecular weight and better tissue penetration. The application of antibody fragmentation technology makes antibodies more advantageous in certain specific situations. For example, smaller antibody fragments can better penetrate into the interior of tumor tissue, achieving targeted therapy of tumor cells; In addition, antibody fragments can also be used as diagnostic reagents or immune detection tools for early diagnosis and monitoring of diseases.

5. Antibody humanization technology: The development of antibody humanization technology is aimed at reducing the immunogenicity of non-human antibodies in the human body. This technology creates chimeric antibodies with human antibody characteristics by combining variable region genes of non-human antibodies with constant region genes of human antibodies. The application of antibody humanization technology has significantly improved the safety and effectiveness of antibody drugs. Humanized antibodies have better tolerance in the human body, reducing the occurrence of immune rejection reactions, thereby improving treatment efficacy and reducing the risk of adverse reactions.

6. Antibody high affinity screening technology: Antibody high affinity screening technology aims to screen antibodies with high affinity from a large number of candidate antibodies. This typically involves screening and identifying antibody libraries using methods such as affinity chromatography, flow cytometry, or high-throughput sequencing. The application of antibody high affinity screening technology enables researchers to quickly find efficient antibodies targeting specific antigens. These high affinity antibodies have higher efficacy and accuracy in disease treatment, biological research, and diagnostic applications.

3. The application of antibody engineering

Antibody engineering has a wide range of applications in disease treatment and diagnosis. By modifying and optimizing antibodies, precise treatment and diagnosis of diseases can be achieved.

In disease treatment, the application of antibody engineering mainly includes tumor immunotherapy, infectious disease treatment, and autoimmune disease treatment. Effective disease control can be achieved by designing highly efficient antibodies that can kill tumor cells, neutralize pathogens, or regulate immune function. For example, antibody drugs designed for tumor cell specific antigens can inhibit tumor development by blocking tumor cell growth signals, inducing cell apoptosis, and other means.

In the field of disease diagnosis, the application of antibody engineering is mainly reflected in the discovery of biomarkers and early diagnosis. By designing and optimizing diagnostic antibodies with high specificity and sensitivity, early detection and accurate diagnosis of diseases can be achieved. These diagnostic antibodies can not only be used for serological testing, but also for various diagnostic methods such as histopathology and imaging.

In addition, antibody engineering plays an important role in drug development, biosensors, and other fields. By utilizing the specificity and affinity of antibodies, efficient screening of drug molecules and the construction of biosensors can be achieved, providing strong support for drug development and biomedical research.

Antibody engineering, as an emerging biotechnology discipline, provides powerful tools for the treatment and diagnosis of diseases by modifying and optimizing antibody molecules. With the launch of the Beacon Optofluidic System by Redbert (Beijing) Biotechnology Co., Ltd., you can save a lot of screening time and greatly reduce production costs. The conventional use of hybridoma or phage display technology usually takes 3-6 months, but Beacon Optofluidic System equipment only takes 3 days to obtain specific antibody sequences. A single plasma cell can be directly isolated and detected in a 0.5nl system, from which target cells expressing specific antibodies can be screened, and their heavy and light chain mRNA can be obtained. These mRNA can be directly used for sequencing and optimization after reverse transcription. Through continuous technological innovation and optimization, it is believed that in the near future, antibody engineering will make greater contributions to the cause of human health.

* The above content is collected online for reference only. If the article on this website involves copyright or other issues, please contact us in a timely manner and we will handle it as soon as possible!